FOR IMMEDIATE RELEASE
- New fellowship integrates regenerative medicine, emerging biotechnology, longevity medicine, and artificial intelligence
- Program targets physicians and point-of-care regenerative medicine providers
- Curriculum reflects ISSCA’s continued investment in advanced physician credentialing
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a comprehensive new fellowship designed for physicians and point-of-care regenerative medicine providers.
The curriculum integrates regenerative medicine modalities, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence — reflecting what ISSCA describes as the increasingly multidisciplinary nature of modern regenerative medicine practice.
ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries. The new fellowship is positioned as the organization’s most comprehensive credential to date, intended to prepare physicians for the convergence of clinical practice, biotechnology, and computational tools.
“The physicians who will lead this field aren’t going to specialize in just one modality — they’ll need to be fluent across regenerative medicine, biotechnology, and increasingly, AI-driven clinical tools,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This fellowship is ISSCA’s answer to that shift.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
